Your session is about to expire
← Back to Search
VISIBLE Trial Summary
This trial will test whether the drug guselkumab is better than placebo at improving the signs and symptoms of psoriasis in people with dark skin.
- Plaque Psoriasis
- Scalp Psoriasis
VISIBLE Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
VISIBLE Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2020 Phase 4 trial • 1027 Patients • NCT03573323
Awards & Highlights
VISIBLE Trial Design
Find a Location
Who is running the clinical trial?
- You are scheduled to receive light therapy or medication for psoriasis treatment.You are allergic to guselkumab or its ingredients.You have been diagnosed with plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before starting the study.You do not identify as white or Caucasian.You are eligible for light therapy or medical treatment for psoriasis.You have a history or are currently experiencing severe and uncontrolled medical conditions that affect your organs, brain, blood, hormones, joints, or mental health.You agree not to get a live virus or bacterial vaccine during the study or within 12 weeks after the study is over.You cannot receive any live virus or bacteria vaccines during the study or for 12 weeks after the study ends.You have types of psoriasis that are not the common plaque type, such as erythrodermic, guttate or pustular psoriasis.You have been diagnosed with plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before starting the study drug.You identify as a person of color, not white/Caucasian.
- Group 1: Cohort A: Moderate-to-severe Plaque Psoriasis
- Group 2: Cohort B: Moderate-to-severe Scalp Psoriasis
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there different hospitals or research facilities testing this in different states?
"Patients are being accepted by Dr. Lorne E. Albrecht in Surrey, British Columbia, Cahaba Research Inc in Birmingham, Alabama and Tory P. Sullivan, M.D., PA in North Miami Beach, Massachusetts, Alabama and Tory P. Sullivan, M.D., PA in North Miami Beach, Massachusetts as well as at 100 other medical facilities"
What is the status of Guselkumab in regards to government regulation?
"There is some evidence to support Guselkumab's efficacy, as this is a Phase 3 trial. Furthermore, the safety of Guselkumab has been supported by multiple rounds of data collection, so it received a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends